Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nedaplatin versus cisplatin concurrent with postoperative radiotherapy for high-risk locally advanced head and neck squamous cell carcinoma
ChiCTR1900021439Phase 3Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Mar 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nedaplatin and cisplatin in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: 2-year progression-free survival rate. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
nedaplatincisplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR1900021439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021439.